The PennZone

  • Home
  • Non-profit
  • Education
  • Business
  • Technology
  • Construction
  • Health
  • Software
  • Entertainment

Beneficience.com Legacy PR Announces Dr. Burd Renowned Diabetes Scientist, Biochemist-entrepreneur and Dexcom Founder, client
The PennZone/10216335

Trending...
  • KT Medical Staffing Expands Concierge Nursing and Private Duty Nursing Services in Orange County
  • All About Technology Celebrates 25 Years of Bridging Detroit's Digital Divide
  • T. Jones Group Named Finalist Across Multiple Categories at the 2026 Georgie Awards
Beneficience Com Announces Dr John Burd, Renowned Dr John Burd Lysulin© Dr Burd Wonder Spray Skin Rescue 8oz Skin Rescue Lysulin© Products Beneficience.com Legacy PR
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.

SAN DIEGO - PennZone -- About John Burd, PhD:

Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc.  In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes.   The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications.  In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.

Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes.  In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million.  In 2020 DexCom had a market cap of over $40 billion.  From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.

Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market.  LXN was sold to Johnson and Johnson in 2000.

More on The PennZone
  • Sugar Land's Social Scene Gets a Boost: Pep's Backyard Set to Open Near Constellation Field
  • Joseph Nybyk (AKA Joseph Neibich) Guests On Octopus TV
  • Mutant-Fueled Bio-Cyberpunk Shooter HoverGrease 2 Launches May 22
  • Triple-Digit Growth, OTCQX Market Upgrade and a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation: Stock Symbol: CDIX
  • XRPPower Continues Strengthening Its Global AI-Powered Blockchain Ecosystem

Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance.  MAST Immunosystems was purchased by Hitachi Chemical in 1997.  Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).

Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products.  He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin.  In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.

Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

JOHN F. BURD, Ph.D.

Founder & CEO Lysulin, Inc and Wonder Spray, llc.

More on The PennZone
  • Lick Introduces Pineapple Flavored Massage Oil — A Tropical Date Night Favorite Available on Amazon
  • FutureLot Powers ADU Wizard for Massachusetts Clean Energy Center's Statewide ADU Resource Center
  • ICT Innovations Releases ICTPBX Community Edition as Open Source Under Mozilla Public License 2.0
  • Brett Furman Expands AI and Marketing Team to Better Help Home Sellers Navigate the Future of Online Search
  • Maryland Personal Injury Firm Earns National Recognition in 2026 ELA Awards

4930 Bradshaw Court, San Diego, CA  92130
Phone: 619-992-2873

Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)

Learn more about Dr. Burd's products below...

Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8



Lysulin video:  https://www.youtube.com/watch?v=PK3CkMty6RE



Running A1c test: https://tinyurl.com/y379jbla

Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos

Follow Burd's PR News at http://Beneficience.com

MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd

Contact
Dr. Tracey Bond, MPRL
Certified Publicist of Record
for John Burd, PhD
***@beneficience.com


Source: Beneficience.com Legacy PR
Filed Under: Business, Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Avery Headley Leads Major Stabilization and Modernization Initiative Across Bronx Affordable Housing Portfolio
  • NewReputation's AI Sentiment Analysis Tool Reaches 2,500 Users as Businesses Demand Clearer Brand Intelligence
  • CAPO Supply Announces Opening of Second Location in New Castle, Pennsylvania
  • $224 Billion Growing Market in Life Settlements Presents Major Opportunity for New Policy Acquisition Business Plan: DLT Resolution Stock Symbol: DLTI
  • Fyt-02 Launches on Kickstarter The Smart Sensor That Turns Any Chair Into a Posture & Movement Track
  • YieldOMega Launches $DOUB Airdrop Campaign Ahead of TimeCurve Launch
  • Kaltra Expands Microchannel Water Coil Line for U.S. HVAC Market With New Corrosion-Resistant Tube Technology
  • Brewtay Coffee Partners with Alex's Lemonade Stand to Fuel Penn Wynne Volunteers
  • White Coat Growth Launches to Help Medical Practices Attract More Patients and Scale with Confidence
  • Collectibles EvoRelic Celebrates Stellar 4.8-Star Customer Rating
  • Phoenix Hip-hop Artist Rhymi Hits 23k Monthly Listeners 12 Days After Album Release
  • Pediatrician Launches "Confessions of a Detective Doctor" Children's Book Series
  • Integrated Maintenance Platforms Are Transforming Aircraft Operations
  • T. Jones Group's Cameron Jones Serves as Judge for the 2026 CHBA National Awards for Housing Excellence
  • Derek Advanced Tracking Systems Revolutionizes Asset Monitoring with Advanced Technology
  • The AI Direction Deficit: TripleTen Study Finds Staff Get Told to Use AI — But Not Trained to Use It
  • Edwards & Virginia Business Systems Announces Leadership Appointments
  • $29.8 Million Record Setting Q1 with Boosted Annual Guidance to $160 Million for Expanding Pre-Owned Boat Dealer: Off The Hook YS, Inc. N Y S E: OTH
  • All About Technology Celebrates 25 Years of Bridging Detroit's Digital Divide
  • iatroX surpasses 500,000 clinical queries and expands specialist exam coverage

Popular on PennZone

  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • People & Stories/Gente y Cuentos Welcomes Two New Trustees as Organization Enters 54th Year and Expands Community Reach
  • New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
  • Strategic Talent Associates Launches THE ALIGNED RESET™
  • AWARENESS TO WELLNESS: Imhotep Institute Charter High School
  • Assymetrix Launches the Deepest Independent Prediction Market Data API
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • New Homesites Released at Heritage at Manalapan Featuring Scenic Golf Course Views
  • Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities

Similar on PennZone

  • Sugar Land's Social Scene Gets a Boost: Pep's Backyard Set to Open Near Constellation Field
  • Triple-Digit Growth, OTCQX Market Upgrade and a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation: Stock Symbol: CDIX
  • XRPPower Continues Strengthening Its Global AI-Powered Blockchain Ecosystem
  • SteelTree Announces Launch of Its Operational Decision Intelligence Service
  • Advanced AI Capabilities Reflected by Upcoming Company Name and Stock Symbol Change for Evolving Pre-Owned Boat Dealer: Off The Hook YS: N Y S E: OTH
  • AI-Driven Defense Expansion, Autonomous Systems and Israeli Aerospace Manufacturing Platform: VisionWave Holdings (N A S D A Q: VWAV)
  • Raymond Lavine, Extended Care Benefits Advisor and Author, to Appear on National Television Series Moving America Forward
  • NaturismRE Launches Structured Nudism & Naturism Encyclopedia, Aiming to Reframe Public Understanding
  • AiBT Advisory Launches AI Deployment Firm for the Mid-Market Companies Big AI Left Behind
  • AI Is Closing the Gap Between Offshore Virtual Assistants and Onshore Staff
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us